• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评价肾移植受者移植后早期的虚拟护理。

Evaluation of Virtual Care in Kidney Transplant Recipients in the Early Posttransplant Period.

机构信息

Department of Nephrology, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.

Department of Nephrology and Kidney Transplant, Armed Forces Hospital, Taif, Saudi Arabia.

出版信息

Clin Transplant. 2024 Sep;38(9):e15459. doi: 10.1111/ctr.15459.

DOI:10.1111/ctr.15459
PMID:39315693
Abstract

BACKGROUND

Though virtual care was widely adopted during the COVID-19 pandemic, evidence to support its use in kidney transplant recipients early after transplantation is limited.

METHODS

We conducted a retrospective cohort study comparing post kidney transplant outcomes in patients who received in-person transplant care before the COVID-19 pandemic with those who received mainly virtual transplant care during the COVID-19 pandemic. The usual-care group included 69 patients who received a kidney transplant from March 1, 2019 to September 1, 2019, and the virtual-care group included 64 patients who received a kidney transplant from September 1, 2020 to March 1, 2021.

RESULTS

At 6 months, five patients in the usual-care group and three patients in the virtual-care group died. There was one graft loss and one episode of acute rejection in the usual-care group, and two episodes of acute rejection in the virtual-care group (p = 0.60). Estimated glomerular filtration rate was higher for patients in the virtual-care group (59 mL/min/1.73 m vs. 52 mL/min/1.73 m, p = 0.046) and serum creatinine was not different (138 µmol/L vs. 127 µmol/L, p = 0.27). There was no difference in mean blood pressure or hospitalizations.

CONCLUSION

Outcomes were similar among recipients of a kidney transplant prior to the COVID-19 pandemic when care was mainly in person and during the pandemic when care was mainly virtual, without a signal of harm. Patient and donor selection may have led to unmeasured differences between groups.

摘要

背景

尽管虚拟护理在 COVID-19 大流行期间得到了广泛应用,但在肾移植受者移植后早期使用虚拟护理的证据有限。

方法

我们进行了一项回顾性队列研究,比较了 COVID-19 大流行前接受面对面移植护理的肾移植受者和 COVID-19 大流行期间主要接受虚拟移植护理的肾移植受者的移植后结局。常规护理组包括 69 名于 2019 年 3 月 1 日至 2019 年 9 月 1 日接受肾移植的患者,虚拟护理组包括 64 名于 2020 年 9 月 1 日至 2021 年 3 月 1 日接受肾移植的患者。

结果

在 6 个月时,常规护理组有 5 名患者死亡,虚拟护理组有 3 名患者死亡。常规护理组发生 1 例移植物丢失和 1 例急性排斥反应,虚拟护理组发生 2 例急性排斥反应(p = 0.60)。虚拟护理组患者的估计肾小球滤过率较高(59 mL/min/1.73 m 2 比 52 mL/min/1.73 m 2 ,p = 0.046),而血清肌酐无差异(138 µmol/L 比 127 µmol/L ,p = 0.27)。两组患者的平均血压或住院率无差异。

结论

在 COVID-19 大流行前主要采用面对面护理的肾移植受者和在大流行期间主要采用虚拟护理的肾移植受者中,结局相似,没有危害的信号。患者和供体的选择可能导致组间存在无法衡量的差异。

相似文献

1
Evaluation of Virtual Care in Kidney Transplant Recipients in the Early Posttransplant Period.评价肾移植受者移植后早期的虚拟护理。
Clin Transplant. 2024 Sep;38(9):e15459. doi: 10.1111/ctr.15459.
2
Is COVID-19 infection more severe in kidney transplant recipients?新冠病毒(COVID-19)感染在肾移植受者中更严重吗?
Am J Transplant. 2021 Mar;21(3):1295-1303. doi: 10.1111/ajt.16424. Epub 2021 Jan 28.
3
COVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic.肾移植受者中的 COVID-19:来自大流行前两波的多中心经验。
BMC Nephrol. 2022 May 12;23(1):183. doi: 10.1186/s12882-022-02784-w.
4
Outcomes of Deceased Donor Kidney Recipients From the Same Donor Based on Donor-Recipient Sex Discordance.基于供受者性别不一致的同一位供体的已故供体肾脏受者的结局。
Clin Transplant. 2024 Jul;38(7):e15409. doi: 10.1111/ctr.15409.
5
Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.用于治疗肾移植受者中已存在的和新发糖尿病的降糖药物。
Cochrane Database Syst Rev. 2017 Feb 27;2(2):CD009966. doi: 10.1002/14651858.CD009966.pub2.
6
Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.钙调磷酸酶抑制剂转换为以贝利尤单抗为基础的免疫抑制方案在 HLA 致敏肾移植受者中的疗效。
Transplantation. 2020 Jul;104(7):1500-1507. doi: 10.1097/TP.0000000000002976.
7
Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study.降低低免疫风险肾移植受者的缓释他克莫司剂量会增加排斥反应风险及供者特异性抗体的出现:一项随机研究。
Am J Transplant. 2017 May;17(5):1370-1379. doi: 10.1111/ajt.14109. Epub 2017 Jan 3.
8
Belatacept for kidney transplant recipients.用于肾移植受者的贝拉西普。
Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD010699. doi: 10.1002/14651858.CD010699.pub2.
9
Clinical relevance of preformed IgG and IgM antibodies against donor endothelial progenitor cells in recipients of living donor kidney grafts.活体供肾移植受者体内针对供体内皮祖细胞的预先形成的IgG和IgM抗体的临床相关性。
Clin Transplant. 2016 Feb;30(2):124-30. doi: 10.1111/ctr.12665. Epub 2015 Dec 16.
10
Association of BKV viremia and nephropathy with adverse alloimmune outcomes in kidney transplant recipients.BK 病毒血症和肾病与肾移植受者不良同种免疫结局的关联。
Clin Transplant. 2024 May;38(5):e15329. doi: 10.1111/ctr.15329.